| Drug Name |
Gemifloxacin mesylate |
| Drug ID |
BADD_D01014 |
| Description |
Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth. |
| Indications and Usage |
For the treatment of bacterial infection caused by susceptible strains such as S. pneumoniae, H. influenzae, H. parainfluenzae, or M. catarrhalis, S. pneumoniae (including multi-drug resistant strains [MDRSP]), M. pneumoniae, C. pneumoniae, or K. pneumoniae. |
| Marketing Status |
approved; investigational |
| ATC Code |
J01MA15 |
| DrugBank ID |
DB01155
|
| KEGG ID |
D02471
|
| MeSH ID |
D000077735
|
| PubChem ID |
9588170
|
| TTD Drug ID |
D0VR7W
|
| NDC Product Code |
68801-320; 50370-0021 |
| UNII |
X4S9F8RL01
|
| Synonyms |
Gemifloxacin | 7-(3-aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid | Factive | Gemifloxacin Mesylate | SB-265805 | SB265805 | SB 265805 | LB 20304 | LB-20304 | LB20304 |
